ClinicalTrials.gg
Not yet recruitingNCT06520540Updated Jul 25, 2024

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

A Phase 1 interventional study of HDM1002 100 mg QD 12weeks and HDM1002 200 mg QD 12weeks in Glucagon-Like Peptide-1 Receptor Agonists, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

  • To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
02

Conditions studied

  • Glucagon-Like Peptide-1 Receptor Agonists

Keywords

  • Glucagon-Like Peptide-1 Receptor Agonists
  • HDM1002 tablet
  • Chinese overweight and obese adult
03

In context

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Chinese subjects aged 18 to 60 years (including 18 years and 60 years old), either male or female subjects;
  2. at 24.0 to 36.0 kg at screening and at random / m2Between (including 24.0 and 36.0 kg / m2);
  3. For fertile subjects, female subjects from 14 days before the form (ICF) to 30 days after the last administration, male subjects within 90 days after the ICF to the last administration, without birth planning and agreed to highly effective (see Section 5.2.3 for details);
  4. Ability to understand the procedures and methods of this study, voluntarily sign the ICF, and be willing to strictly comply with the clinical trial protocol requirements to complete the relevant process.

Exclusion Criteria:

Selection criteria:

Subjects must meet all of the following inclusion criteria to be enrolled in this study:

  1. Chinese subjects aged 18 to 60 years (including 18 years and 60 years old), either male or female subjects;
  2. BMI at 24.0 to 36.0 kg at screening and at random / m2Between (including 24.0 and 36.0 kg / m2);
  3. For fertile subjects, female subjects from 14 days before the informed consent form (ICF) to 30 days after the last administration, male subjects within 90 days after the ICF to the last administration, without birth planning and agreed to highly effective contraception (see Section 5.2.3 for details);
  4. Ability to understand the procedures and methods of this study, voluntarily sign the ICF, and be willing to strictly comply with the clinical trial protocol requirements to complete the relevant process.

Exclusion criteria:

Subjects meeting either of the following criteria will be excluded:

  1. 5% self-reported or documented body weight change within 3 months prior to randomization;
  2. Previous diagnosis of type 1, type 2 or any other type of diabetes; or using hypoglycemic drugs; or 6.5% at screening or fasting glucose 7.0 mmol/L; or fasting glucose \<3.9 mmol / L;
  3. Diagnosis of overweight or obesity caused by other diseases or drugs;
  4. History or family history of medullary thyroid carcinoma, thyroid C cell hyperplasia, or multiple endocrine adenomatosis type 2;
  5. History of chronic pancreatitis or onset of acute pancreatitis within 3 months before signing an ICF;
  6. History of acute gallbladder disease within 3 months before signing the ICF;
  7. Any malignant tumor within 5 years before signing the ICF (except for basal cell carcinoma that has received curative treatment and is considered cured);
  8. Combination of cardiovascular and cerebrovascular diseases with obvious clinical significance, including but not limited to angina pectoris, MI, stroke or severe peripheral artery circulation disorder within 1 year before signing ICF; presence of risk factors of torsade ventricular tachycardia; presence of untreated serious arrhythmia, such as sick sinus syndrome, second or third degree atrioventricular block; or screening systolic blood pressure 160 mmHg, or diastolic blood pressure 100 mmHg;
  9. In the judgment of the investigator, the subjects had some diseases or conditions that may affect drug absorption, such as active inflammatory bowel disease, gastrectomy resection, any intestinal area resection, etc.;
  10. Those who had major surgery within 3 months prior to signing the ICF or who performed surgery during the planned study;
  11. According to the investigator, the presence of concomitant diseases, including but not limited to the respiratory system, digestive system, nervous system, urogenital system, blood system, endocrine system and other diseases;
  12. Known intolerance or to a GLP-1 receptor (GLP-1R) agonist;
  13. Within 3 months prior to ICF signing, the following drugs were used and significantly weight, including but not limited to: a. Drugs or products with weight loss effects, such as GLP-1R agonists (liraglutide, selmeaglutide, benallutide, etc.), orlistat, naltrexone / bupropion, etc.; b. Drugs or products that increase body weight, such as systemic , psychiatric medication (e. g., tricyclic antidepressants, paroxetine, olanzapine, clozapine, mirtazapine, valproic acid and its derivatives, etc.); c. Any Chinese patent medicine or Chinese herbal medicine that may affect the body weight;
  14. Any drug used within 14 days or may affect the pharmacokinetics of HDM1002 tablets (whichever is older) (see Section 6.4.2 and Section 6.4.3), including prescription drugs, over-the-counter drugs, Chinese herbal medicines, proprietary Chinese medicines, or nutritional supplements;
  15. Subjects taking lipid-lowering drugs within 30 days before signing ICF;
  16. Have participated in any clinical trial within 30 days before randomization or within 5 half-lives after the last dose (whichever is older) (except for signed ICF with no drug or device intervention);
  17. Any of the laboratory indicators during the screening period met the following criteria:

    1. \<110 g / L for women and \<120 g / L for men;
    2. glutamate aminotransferase> 2.0 (ULN), or aminotransferase> 2.0 ULN, or alkaline phosphatase> 1.5 x ULN, or total > 1.5 ULN (subjects with Gil bert's syndrome can participate in this study with direct bilirubin ULN);
    3. Triglycerides> 5.6 mmol / L;
    4. Calcitonin: 35 ng/L;
    5. Thyroid-stimulating hormone> 6.0 mIU / L or \<0.4 mIU / L;
    6. Blood amylase or lipase> ULN;
    7. Estimated (eGFR) \<60 mL/min/1.73m, calculated from the Cooperative Epidemiological Study of Chronic Kidney Disease (CKD-EPI) formula2;
  18. The following abnormalities were present during the screening period: > 450 ms, or heart rate \<50 beats / min or> 100 beats / min;
  19. Positive test results for virus surface antigen, virus antibody or treponema pallidum antibody, or non-negative for ;
  20. More than 5 cigarettes per day in the 3 months before signing the ICF;
  21. Those who had drunk alcohol abuse within 1 year before signing the ICF (i. e., drinking more than 14 standard units per week for men, women drinking more than 7 standard units per week, 1 standard unit containing 14 g alcohol, such as 360 ml beer or 150 ml alcohol of 40 ml), or prerandomized alcohol breath test or blood alcohol test positive;
  22. History of addictive drug abuse within 1 year before signing the ICF, or positive urine drug test before randomization;
  23. Within 7 days prior to randomization, subjects reported having consumed grapefruit or products containing grapefruit;
  24. Pregnancy (blood human chorionic gonadotropin 5 mIU / ml or positive urine pregnancy test) or lactating women;
  25. The subject is the investigator or other relevant investigator of the project;
  26. In the opinion of the investigator, the subject was not fit to participate in any other condition of the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    HDM1002 100 mg

    Drug: HDM1002 100 mg QD 12weeks · Drug: HDM1002 200 mg QD 12weeks · Drug: HDM1002 400 mg QD 12weeks,Q 2W for titration · Drug: HDM1002 400 mg QD 12weeks,Q 3W for titration

  • Active comparator
    HDM1002 200 mg

    Drug: HDM1002 200 mg QD 12weeks · Drug: HDM1002 400 mg QD 12weeks,Q 2W for titration · Drug: HDM1002 400 mg QD 12weeks,Q 3W for titration

  • Active comparator
    HDM1002 400 mg

    Drug: HDM1002 400 mg QD 12weeks,Q 2W for titration · Drug: HDM1002 400 mg QD 12weeks,Q 3W for titration

  • Placebo comparator
    Placebo

    Device: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. TEAEs, SAEs, AEs leading to withdrawal, and AEs leading to death, AEs of special interest

    TEAEs and SAEs (incidence, severity and causal relationship), AEs leading to withdrawal, and AEs leading to death, AEs of special interest

    Time frame: Baseline, Week 12

Secondary outcomes

  1. change in body weight from baseline at Day 85

    Weight during treatment from baseline

    Time frame: Baseline, Week 12

  2. change in BMI from baseline at Day 85

    change in body mass index (BMI) from baseline

    Time frame: Baseline, Week 12

  3. change in waist circumference from baseline at Day 85

    Change in waist circumference from baseline

    Time frame: Baseline, Week 12

  4. Plasma PK parameters

    Cmax

    Time frame: Baseline, Week 12

  5. Plasma PK parameters

    Tmax

    Time frame: Baseline, Week 12

  6. Plasma PK parameters

    AUC0-last

    Time frame: Baseline, Week 12

  7. Plasma PK parameters

    AUCtau

    Time frame: Baseline, Week 12

  8. Plasma PK parameters

    AUC0-24h

    Time frame: Baseline, Week 12

  9. Plasma PK parameters

    AUC0-∞

    Time frame: Baseline, Week 12

  10. Plasma PK parameters

    t1/2z

    Time frame: Baseline, Week 12

  11. Plasma PK parameters

    CL/F

    Time frame: Baseline, Week 12

  12. Plasma PK parameters

    Vz/F

    Time frame: Baseline, Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Nov 2024, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 25, 2024
StartEst.
Jul 28, 2024
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06520540
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
Jul 28, 2024 (estimated)
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jul 25, 2024

Study contacts

Wenwen Tu
Contact
tuwenwen@eastchinapharm.com
+86-0571-89903388
Xiaoying Li
principal investigator · Zhongshan Hospital, Shanghai, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion